Return on Federal Biotech Investment Working, NIH Says
Thirteen months ago, the General Accounting Office issued an unfavorable report on the licensing and royalty returns the National Institutes of Health (NIH) receive for commercialization of technologies resulting from federal funds (see: http://www.ssti.org/Digest/2000/081800.htm).